Biotech Values

[iwfal]

PLX4032 was designed to target a very specific mutation, the BRAF v600e mutation

Seems odd that something that specific (i.e. specific to a specific kind of defect in a specific gene) would be harmful enough to cause large rates of cancer in squamous cells. Are you sure it isn't a more generalized BRAF effector - but only applied in the trials to those with BRAF mutations in their cancer? (Obviously I will need to read the NEJM or JAMA (forget which) paper because it is so interesting)